Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
BUSINESS
Eisai’s Q1 Sales Jump 20% on Growth of 4 Global Brands
Eisai registered a group sales growth of 20.1% year on year in April-June driven by its four global products. The company also posted strong growth in profits. In the first-quarter of FY2021, Eisai posted consolidated sales of 198,894 million yen…
To read the full story
Related Article
- Eisai’s H1 Operating Profit Spikes on Lenvima Growth, Divestment Gain
November 8, 2023
- Eisai’s Q1 Operating Profit Jumps on Lenvima Growth, Lower Aduhelm Cost
August 3, 2023
- Eisai’s FY2022 Sales Slip 1.6% on Lower Milestones, Year-Before Gain
May 16, 2023
- Eisai Cuts FY2022 Earnings Forecast on FX, Subpar Mainstay Results
May 10, 2023
- Eisai’s 9-Month Profits Sink after One-Time BMS Alliance Gain a Year Ago
February 7, 2023
- Eisai Scores Sales, Profit Growth on Lenvima Boon in FY2021 despite Aduhelm Setback
May 16, 2022
- Eisai’s April-December Sales Zoom 13.4% on Lenvima Growth Overseas
February 4, 2022
- Eisai’s H1 Sales Rise 14.3% on 4 Global Brands, ADC License Income
November 2, 2021
BUSINESS
- Keytruda Maintains Top-Selling Title in Japan in July-September: IQVIA
November 14, 2024
- Mitsubishi Chemical Looking for “Best Partners” for Pharma Biz: CEO
November 14, 2024
- Lilly Japan Halts Manufacturing of Strattera over Nitrosamine Impurities
November 14, 2024
- Nippon Shinyaku Bags Japan, US Rights to Atsena’s Gene Therapy
November 14, 2024
- Daiichi Sankyo Replaces FDA Lung Cancer Filing for TROP2-Directed ADC
November 13, 2024
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…